ATP4A
ENSG00000105675
Target class
Transporter
Chromosome
19
Approved drugs
10
Clinical candidates (approved and in development)
13
- Approved drugs
- 10
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- No
- Other names
- ATP6A
- Target name
- ATP4A
- Gene name
- ATPase H+/K+ transporting subunit alpha
- Gene symbol
- ATP4A
- Protein name
- Potassium-transporting ATPase alpha chain 1 (EC 7.2.2.19) (Gastric H(+)/K(+) ATPase subunit alpha) (Proton pump)
- Gene biotype
- Protein coding
- Gene family
- ATPase H+/K+ transporting
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 7
- Highest tissue expression
- 1,206.25
- Tissue specificity (Gini)
- 0.976
- Tissue specificity (tau)
- 0.999
- KEGG gene identifiers
- hsa:495
- Reactome pathways
- R-HSA-936837
- Protein interaction confidence
- 0.83575
- Protein interaction partners
- 28
- End position
- 35563658
- Start position
- 35550031
- Chromosome
- 19
- Strand
- Reverse
- Apical cell membrane
- Multi-pass membrane protein . Note=Localized in the apical canalicular membrane of parietal cells (PubMed:24188822). .
Publication evidence
- PubMed 24188822
- Tissue specificity (tau)
- 0.999353
- Expression inequality (Gini)
- 0.975935
Expression in transcripts per million
- Stomach
- 1,206.25
- Adrenal Gland
- 9.83
- Brain - Cerebellar Hemisphere
- 8.63
- Brain - Cerebellum
- 8.23
- Pancreas
- 5.4
Expression in transcripts per million
- Stomach1,206.25
- Adrenal Gland9.83
- Brain - Cerebellar Hemisphere8.63
- Brain - Cerebellum8.23
- Pancreas5.4
- Testis2.02
- Brain - Cortex1.54
- Brain - Frontal Cortex (BA9)0.86
- Thyroid0.85
- Cells - EBV-transformed lymphocytes0.74
- Pituitary0.29
- Brain - Anterior cingulate cortex (BA24)0.26
- Bladder0.17
- Cervix - Ectocervix0.16
- Ovary0.15
- Esophagus - Mucosa0.15
- Small Intestine - Terminal Ileum0.13
- Spleen0.11
- Uterus0.09
- Brain - Spinal cord (cervical c-1)0.09
- Vagina0.09
- Fallopian Tube0.09
- Breast - Mammary Tissue0.08
- Colon - Transverse0.08
- Prostate0.08
And 29 more, listed on the interactive page.
Biological processes
- GO:0034220
- GO:0005576
- GO:0005886
- GO:0016324
Molecular functions
- GO:0008900
Related records
Trials (1,435)
- "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
- +AGIL Barcelona: Integrated Care for Community-Dwelling Frail Older Adults
- 10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication
- 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
- 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy
- 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication
- 15-day Sequential Therapy for Helicobacter Pylori Infection in Korea
- 24-h Energy Expenditure and Anti-obesity Medication
- 3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects
- 5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection
- 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication
- 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori
- A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
- A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet
- A Bioequivalence Study of 2 Formulations of Rabeprazole Sodium and Evaluation of the Effect of Food on Rabeprazole Sodium in Healthy Adult Volunteers
- A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)
- A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults
Drugs (17)
- Abeprazan Potassium-transporting ATPase inhibitor
- Dexlansoprazole Potassium-transporting ATPase inhibitor
- Esomeprazole Potassium-transporting ATPase inhibitor
- Esomeprazole magnesium Potassium-transporting ATPase inhibitor
- Esomeprazole sodium Potassium-transporting ATPase inhibitor
- Esomeprazole strontium Potassium-transporting ATPase inhibitor
- Ilaprazole Potassium-transporting ATPase inhibitor
- Lansoprazole Potassium-transporting ATPase inhibitor
- Omeprazole Potassium-transporting ATPase inhibitor
- Omeprazole magnesium Potassium-transporting ATPase inhibitor
- Pantoprazole Potassium-transporting ATPase inhibitor
- Pantoprazole sodium Potassium-transporting ATPase inhibitor
- Rabeprazole Potassium-transporting ATPase inhibitor
- Rabeprazole sodium Potassium-transporting ATPase inhibitor
- Tegoprazan Potassium-transporting ATPase blocker
- Vonoprazan Potassium-transporting ATPase inhibitor
- Vonoprazan fumarate Potassium-transporting ATPase inhibitor